Roche Diagnostics Amplicor, Cobas HCV RNA Tests To Launch By October
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics' Amplicor Version 2.0 and Cobas Amplicor automated Version 2.0 hepatitis C (HCV) qualitative RNA tests are expected to launch Sept. 28. The firm announced FDA approval of the tests July 9.
You may also be interested in...
Roche Amplicor, Cobas HCV RNA Tests Approvable With Conditions - Panel
Roche Molecular Systems should include in labeling for the Amplicor Version 2.0 and Cobas Amplicor automated Version 2.0 hepatitis C tests a warning that heparin use could lead to an "HCV not-detected" result, FDA's Microbiology Devices Panel agreed in recommending FDA approval at a July 28 meeting.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.